MARKET

RPRX

RPRX

Royalty Pharma plc
NASDAQ

Real-time Quotes | Nasdaq Last Sale

38.38
+0.41
+1.08%
After Hours: 38.38 0 0.00% 17:47 09/16 EDT
OPEN
37.90
PREV CLOSE
37.97
HIGH
38.64
LOW
37.68
VOLUME
3.15M
TURNOVER
--
52 WEEK HIGH
53.23
52 WEEK LOW
34.80
MARKET CAP
22.85B
P/E (TTM)
15.51
1D
5D
1M
3M
1Y
5Y
Avillion announces positive results in MANDALA and DENALI Phase III trials of AstraZeneca's PT027, a fixed-dose combination of albuterol and budesonide, demonstrating significant benefits for asthma patients
/PRNewswire/ -- Avillion LLP, a drug development company focused on the co-development and financing of pharmaceutical candidates, from proof-of-concept through to regulatory approval, announces positive high-level results from the MANDALA and DENALI Phase...
PR Newswire - PRF · 09/09 08:00
Royalty Pharma to Present at Upcoming Investor Conferences
NEW YORK, Sept. 03, 2021 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced that it will participate in the following upcoming investor conferences during the month of September: Citi’s 16th Annual BioPharma Virtual Conference on Thursda...
GlobeNewswire · 09/03 13:00
Evercore Wealth Management, LLC Buys McDonald's Corp, FedEx Corp, Cloudflare Inc, Sells ...
GuruFocus News · 08/24 15:38
Indie Asset Partners, LLC Buys Royalty Pharma PLC, Siren Nasdaq NexGen Economy ETF, Vanguard ...
GuruFocus News · 08/13 18:38
Company News for Aug 12, 2021
Zacks.com · 08/12 13:44
Royalty Pharma (RPRX) Q2 Earnings and Revenues Surpass Estimates
Zacks.com · 08/11 12:55
BRIEF-Royalty Pharma Reports Second Quarter 2021 Results
reuters.com · 08/11 11:21
JNB Advisors LLC Buys Royalty Pharma PLC, iShares Interest Rate Hedged Corporate Bond ETF, ...
GuruFocus News · 08/04 20:38
More
Forecast
Actual (USD)
Estimate (USD)
Income StatementMore
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
Operating (USD)
YoY (%)
Learn about the latest financial forecast of RPRX. Analyze the recent business situations of Royalty Pharma plc through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 9 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average RPRX stock price target is 51.43 with a high estimate of 56.00 and a low estimate of 46.00.
EPS
Institutional Holdings
Institutions: 264
Institutional Holdings: 253.71M
% Owned: 42.61%
Shares Outstanding: 595.38M
TypeInstitutionsShares
Increased
90
18.46M
New
54
6.43M
Decreased
56
18.19M
Sold Out
32
1.54M
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Pharmaceuticals
-0.24%
Pharmaceuticals & Medical Research
+0.11%
Key Executives
Chairman/Chief Executive Officer/Director
Pablo Legorreta
Vice Chairman/Executive Vice President/Director
Christopher Hite
Chief Financial Officer/Executive Vice President
Terrance Coyne
Executive Vice President/General Counsel
George Lloyd
Executive Vice President
James Reddoch
Senior Vice President
Molly Chiaramonte
Senior Vice President
Marshall Urist
Lead Director/Independent Director
Henry Fernandez
Director
M. Germano Giuliani
Director
Rory Riggs
Independent Director
Bonnie Bassler
Independent Director
Errol De Souza
Independent Director
Catherine Engelbert
Independent Director
William Ford
Independent Director
Ted Love
Independent Director
Gregory Norden
Declaration Date
Dividend Per Share
Ex-Div Date
07/16/2021
Dividend USD 0.17
08/19/2021
04/15/2021
Dividend USD 0.17
05/19/2021
01/08/2021
Dividend USD 0.17
02/18/2021
10/15/2020
Dividend USD 0.15
11/19/2020
09/02/2020
Dividend USD 0.15
09/14/2020
About RPRX
Royalty Pharma plc is engaged in investing in late stage biopharmaceutical products. The Company invests in academic institutions, research hospitals and not-for-profits through small and mid-cap biotechnology companies to global pharmaceutical companies. The Company’s portfolio of pharmaceutical investment includes investments in commercial products and development-stage product candidates. Its portfolio investments include AbbVie and J&J’s Imbruvica, Astellas and Pfizer’s Xtandi, Biogen’s Tysabri, Gilead’s HIV franchise, Merck’s Januvia, Novartis’ Promacta, Vertex’s Kalydeco, Orkambi, Symdeko, Trikafta and OXLUMO.

Webull offers kinds of Royalty Pharma plc stock information, including NASDAQ:RPRX real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, RPRX stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading RPRX stock methods without spending real money on the virtual paper trading platform.